Patient Power Hodgkin lymphoma is a treatable cancer, and many patients diagnosed with it will be cured. Though stage does matter when it comes to prognosis, Dipenkumar Modi, M.D. , hematologist and medical oncologist, and member of the Bone Marrow and Stem Cell Transplant and Hematology Oncology Multidisciplinary Teams at Karmanos, shared some promising new therapies and immunotherapies that have helped improve patient outcomes. Read the article here .
Patient Power Often, Hodgkin lymphoma patients experience skin changes, whether it is a side effect from treatment or a symptom from the cancer. Dipenkumar Modi, M.D. , hematologist and medical oncologist, and member of the Bone Marrow and Stem Cell Transplant and Hematology Oncology Multidisciplinary Teams at Karmanos, explained what some of the treatment options are for patients experiencing skin rashes. Read the article here .
Patient Power Research presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting showed lower rates of CLL patients receiving certain fungal infections if Bruton tyrosine kinase (BTK) inhibitors were part of their treatment plan, versus CLL patients who did not have BTK inhibitors as part of their therapy. Dipenkumar Modi, M.D. , hematologist and medical oncologist, and member of the Bone Marrow and Stem Cell Transplant and Hematology Oncology Multidiscipl...
ASH Abstract Achievement Award- 2017
Young Investigator Travel Grant Recipient, Society of Hematologic Oncology (SOHO) Annual Meeting- 2017
Recognition Award, Wayne State University 2016 In the area of Citizenship And Academic Achievement
Clinical Research Award, Wayne State University - 2015
Young Achiever Award, American College of Physicians National Conference- 2014